N-Acetyl GM3 vaccine

Drug Profile

N-Acetyl GM3 vaccine

Alternative Names: N-acetil GM3/VSSP; NAcetilGM3; NAcGM3-VSSP vaccine

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Elea
  • Class AIDS vaccines; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections
  • Discontinued Breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma

Most Recent Events

  • 18 Mar 2011 Clinical development is ongoing for Cancer and HIV infections in Cuba and Argentina
  • 26 Nov 2010 Phase-I/II clinical trials in Lung cancer in Argentina (Parenteral)
  • 28 Mar 2003 This vaccine is available for licensing (http://www.cim.sld.cu)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top